Propanc Biopharma, Inc.
PPCB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PPCB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PPCB
Propanc Biopharma, Inc. is a pre-revenue biopharmaceutical company focused on developing its lead product candidate, PRP, a proenzyme formulation for the treatment of advanced solid tumors, and has not yet initiated clinical trials.
Key risk: Going concern uncertainty
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$3.1M
Cash Runway
—
Lead Asset
prp (Preclinical)
Next Catalyst
—
Financial data as of Mar 31, 2026.
Tracking 1 pipeline candidate for Propanc Biopharma, Inc..
Propanc Biopharma, Inc. is a pre-revenue biopharmaceutical company focused on developing its lead product candidate, PRP, a proenzyme formulation for the treatment of advanced solid tumors, and has not yet initiated clinical trials.
- Lead asset PRP is a proenzyme formulation designed to control or prevent tumor recurrence and spread [sec_mda · as of 2025-11-14].
- The company is preparing for a Phase 1b First-In-Human study in 30-40 advanced cancer patients with solid tumors [sec · filed 2026-07-17].
- As of 2026-03-31, the company reported a net loss of $6.4M, negative shareholders' equity of $3.8M, and total debt of $0.1M [sec].
- The company has a going concern qualification and requires substantial additional funding to continue operations [sec · filed 2026-07-17].
- Propanc completed an underwritten public offering in August 2025, raising $4M in gross proceeds [sec_mda · as of 2025-11-14].
What works
- PRP is based on a novel proenzyme formulation that exerts multiple effects to control or prevent tumors from recurring and spreading [sec_mda · as of 2025-11-14].
- The company has advanced PRP to the stage of preparing for a Phase 1b clinical study, including GMP manufacturing and pharmacokinetics method development [sec · filed 2026-07-17].
- Propanc has built an intellectual property portfolio, including a recent certificate of grant for its proenzyme composition [sec_mda · as of 2025-11-14].
What to weigh
- The company has not yet initiated any clinical trials and has no demonstrated ability to complete large-scale trials, obtain marketing approvals, or commercialize a product [sec · filed 2026-07-17].
- Propanc's financial statements include a going concern qualification, indicating substantial doubt about its ability to continue as a going concern [sec · filed 2026-07-17].
- The company will need substantial additional funding to support its development activities, and failure to raise capital could force delays or elimination of programs [sec · filed 2026-07-17].
- Preclinical and clinical data are susceptible to varying interpretations, and many companies with satisfactory preclinical results have failed to obtain marketing approval [sec_mda · as of 2026-07-17].
From the filings
Quoted directly from source documents.
PRP is the lead product candidate and is a proenzyme formulation.
“Our lead product candidate, PRP, is a variation upon our novel formulation and involves pro-enzymes, the inactive precursors of enzymes.”
SEC MD&A · November 14, 2025
The company is preparing for a Phase 1b study in 30-40 advanced cancer patients.
“preparation of PRP for a Phase 1b First-In-Human study in 30 - 40 advanced cancer patients suffering from solid tumors.”
SEC filings · July 17, 2026
The company has a going concern qualification.
“The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The "Going Concern Qualification" might make it substantially more difficult to raise capital.”
SEC filings · July 17, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — The company's financial statements include a going concern qualification, raising substantial doubt about its ability to continue operations [sec · filed 2026-07-17].
- No clinical trial experience — The company has not yet initiated any clinical trials and has no demonstrated ability to complete pivotal trials or obtain marketing approval [sec · filed 2026-07-17].
- Need for substantial funding — The company requires significant additional capital to fund development and commercialization; failure to raise funds could force program delays or elimination [sec · filed 2026-07-17].
- Regulatory and clinical risks — Preclinical and clinical data are subject to varying interpretations, and many product candidates fail to obtain marketing approval despite satisfactory early results [sec_mda · as of 2026-07-17].
What to watch
- Initiation of the Phase 1b First-In-Human study for PRP in advanced cancer patients [sec · filed 2026-07-17].
- Ability to secure additional financing to support ongoing operations and clinical development [sec · filed 2026-07-17].
- Progress in GMP manufacturing and pharmacokinetics method development for PRP [sec · filed 2026-07-17].
- Any updates on regulatory interactions or intellectual property grants [sec_mda · as of 2025-11-14].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Propanc Biopharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Propanc Biopharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.36 · 0% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4
Total value held
$25K
| Holder | Shares | Value |
|---|---|---|
| jane street group, llc | 143,212 | $15K |
| marex group plc | 67,724 | $7K |
| sassicaia capital advisers llc | 16,000 | $2K |
| xtx topco ltd | 12,098 | $1K |
Short Interest
as of May 22, 2026- % of float
- 3.3%
- Days to cover
- 0.1
- Shares short
- 20,951
- Daily short volume (May 6, 2026)
- 76.0%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PPCB short interestFrequently asked questions
What is the AI investment thesis for Propanc Biopharma, Inc.?
Propanc Biopharma, Inc. is a pre-revenue biopharmaceutical company focused on developing its lead product candidate, PRP, a proenzyme formulation for the treatment of advanced solid tumors, and has not yet initiated clinical trials.
What is Propanc Biopharma, Inc.'s lead drug candidate?
Propanc Biopharma, Inc.'s most advanced tracked candidate is prp (Preclinical) for Pancreatic cancer.
Who is the CEO of Propanc Biopharma, Inc.?
Mr. James Nathanielsz is the chief executive officer of Propanc Biopharma, Inc. (PPCB).
Where is Propanc Biopharma, Inc. headquartered?
Propanc Biopharma, Inc. (PPCB) is headquartered in Camberwell, VIC, Australia.
What therapeutic areas does Propanc Biopharma, Inc. focus on?
Propanc Biopharma, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.